Many investors have lost a lot of money. The bad thing is that Lumsden knew about the danger that the FDA would always use the old Arpida data. They should have started with HABP. So no one will ever give them money for new adventures.
Lumsden knew about the danger that the FDA would use the old Arpida data. That annoyed me most. Since no one will be ready to invest money for times it remains uncertain how the HABP P3 goes and the distribution would also have to be clarified. For me Motif is bankrupt. Scott is right, the AGM will be a highlight. But the management has never invested its own money and rejected the directors dealing with stupid excuses. They knew why. Please discuss further, when the stock rallies, tripples and how bright the future is...
The FDA will not approve Iclaprim with the current datas. They still take the old concerns from the arpida trial. So motif hast todo tue HABP trials. This will cost around 50mln. Money, they dont have. The best case is, Hercules finds a partner, who is willing to invest. Motif might get royalties after. But this might take 4-5 years and the royalties will be small. I doubt, they will find somebody, after it failed now 3times. And you should not forgett, to build up distribution, might cost even more. Look at Achoagen... to discuss here every day, is useless. I'm sure we wont see 5p the next years. Hercules got the warrants, to do a better effort in selling/partnering iclaprim. But do they care? NOOOOOO
Absolutely agree Scott!! And even in this situation, dreamer lumbsden is talking about aquisitions and new possibilities!! No way - even approved AB's cant really make it to the market. How can Iclaprim be different? There will be no fresh money for this sector.
Plus, thats the reason, we never saw the board buying stocks or any participation in an capital increase. They new about the risk and prefered options.. there is a huge medical need for ABs but obvious no environment for pharmas to earn money.
And as you said... Achaogen sold an approved AB for 16mln.. Iclaprim is far away from that. Needs further money and you still have the risk, it doesnt get approved, or can show the right results. And Lumsden dreams about acquiring new assets?? Big bull**** bla bla...
The small US company Achaogen was a great hope: It had developed an antibiotic against resistant germs. But has not survived that.
Ryan Cirz goes through the lab. Apart from the noise of the air conditioning is nothing to hear, the workplaces are empty, the expensive equipment is partly packed in boxes. Until recently, the 40-year-old was chief scientist here. His dream was to research an antibiotic that helps fight off resistant germs and save lives for critically ill patients. Now, in May of this year, Cirz is the last scientist here. He is only responsible for the execution of the company.
Copied that out of an article... please check yourself and the news about Achaogen. This happened to others in the sector as well!!! Only Lumsden will continue and survive with his dreams. Please wake up!!!
All majors steped out of the market. Even Achoagen went bankrupt with an approved AB. Nobody is willing to invest. Distribution is too expansive, profit too low. Motif will never reache blockbuster level. The problem is the market. Really think it is a shame for Motif, it will go bankrupt. I doubt there are investors in this environment around. Scott is right, Lumsden is a dreamer!!!
He only pronounces the truth, but you would rather stay in your fairytale world...
. In addition, we are actively pursuing options to broaden our pipeline as we work to build shareholder value.... How does this week, je you are unable to pay your debt??
Hercules has no big risk. In the negative case you sell iclaprim for 5-7 mlm. The shareholder, however, runs out of funds and the management team is looking for a new employer. If the opposite happens, a big dilution will occur to the shareholder, but he will not lose all his investment.
And we would have seen lost of possible Partners already. Nothing has happened..
The FDA doesnt agree, they see problems, even iclaprim would be strongly needed. Think it goes bust...
They were in talks with potential partners for some years now, since they started for ROW. Interest was nearly sero. Nobody wanted to pay huge upfront and we know, why.
What a bull**** RNS. How can you actively evaluate additional in-licensing and asset acquisition opportunities, when you still need to get the financing done for a 4 times faild medicin? Lumsden is a dreamer and nothing else. Propably they safe their jobs with a new partner, but the old shareholders will loose their money.
Was für community here in the chat. For more than 5 years!!! Wish you all good luck!!
Sold my last shape at 8.7 and were happy I did, but disapointed from the BOD as well. It was to obvious. At this stage I would be Happy if they ever get their financing done. I doubt there will be a partnership ever!!! This thing is gone now and if I would still own stock I would rather sell, then hope ! We hoped for years things would go better and never understood the discount and said its novel. It isnt and BOD knows that, its bullshit!!!
I rather worry about you, as you still play in this high risk stock, to lose everything. At the end, you have nothing to trade anymore. haha
They have written their holdings off. They will not sell at 3p.. Interesting will be, if they still participate in an capital increase, which I doubt now.
First nobody did understand the crl and the reasons for it and we had tonns of disussions. Now we start a discussion about the financing with the same outcome?? If there is a path, it will not take care about the shareholders. Even at 10p it wont be enough...